Saturday 17 October 2026 Export BCRX’s income statement to Excel — free account

BioCryst Pharmaceuticals, Inc.

BCRX Healthcare Drug Manufacturers Specialty & Generic

BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024. In the quarter to June 2026, revenue grew 33.6%, EPS grew 1,450.0%, free cash flow grew 153.2% and total debt rose 15.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

7.79 0.23 −2.87%

Follow BCRX

Alert me

Market cap: $2.1B
P/E: 0.0×
Fwd P/E: −3.5×
Dividend yield: —
F-score: 7/9
Altman Z: 1.83
Beneish M: −2.27
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 4.14

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	3	—	—	2	—	2	—	—	—	—	—

Insider Ownership 13.68%

Capital & Financial Ratios $m

Market Cap 2,050.00

Revenue 940.61

Net Income (384.67)

Free Cash Flow 373.93

Net Debt 486.35

Current Ratio 2.32

Debt/Equity (1.85)

P/E ratio 0.00

Fwd P/E (3.51)

P/S ratio 2.11

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (289.50%)

Next Y EPS Growth 125.20%

Next Y revenue growth (18.83%)

Next 5Y EPS Growth (18.81%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.88%

10-year low 10-year high

EV/Sales against its own 10 years 2.99%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	391	321	275	353
Receivables	57	79	107	111
Inventory	29	8	5	6
Other	—	—	—	—
	496	422	404	485

	2023	2024	2025	Q'26
Payables	21	12	16	11
ST’ Debt	24	33	52	60
Other	—	—	—	—
	150	160	196	209

Compound Annual Growth %

	10y	5y	3y
Sales	33.61%	117.89%	47.82%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	156	218	—	—	—
’25	146	163	159	407	875
’24	93	109	117	132	451
’23	69	82	87	93	331
’22	50	66	76	80	271
’21	19	50	41	47	157
’20	5	3	6	4	18

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(62)	104	—	—	—
’25	(28)	41	42	292	347
’24	(54)	(1)	8	(5)	(52)
’23	(48)	(19)	(20)	(9)	(95)
’22	(78)	(28)	(32)	(24)	(162)
’21	(61)	(25)	(23)	(32)	(142)
’20	(23)	(31)	(38)	(43)	(135)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(62)	104	—	—	—
’25	(28)	41	40	292	345
’24	(54)	(2)	8	(6)	(53)
’23	(48)	(19)	(21)	(9)	(97)
’22	(78)	(28)	(33)	(24)	(163)
’21	(61)	(26)	(24)	(34)	(145)
’20	(23)	(31)	(38)	(43)	(136)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.98)	0.30	—	—	—
’25	0.00	0.02	0.06	1.12	1.21
’24	(0.17)	(0.06)	(0.07)	(0.13)	(0.43)
’23	(0.28)	(0.40)	(0.19)	(0.31)	(1.18)
’22	(0.40)	(0.32)	(0.23)	(0.38)	(1.33)
’21	(0.36)	(0.24)	(0.33)	(0.10)	(1.03)
’20	(0.24)	(0.24)	(0.26)	(0.34)	(1.09)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.63	3.95	4.25	1.38	1.58	7.27	7.61	4.83	4.03	6.00	Analyst estimates 2026–2028 Powerpack
	High	10.24	9.25	9.71	9.95	8.99	18.48	19.99	12.08	8.88	11.31
People
People	Employees	65	85	100	140	246	358	531	536	580	435
	Revenue/emp, $m	0.41	0.30	0.21	0.35	0.07	0.44	0.51	0.62	0.78	2.01
Income, $m
Income, $m	Revenue	26	25	21	49	18	157	271	331	451	875
	Gross margin, %	91.28	95.47	100.00	92.37	91.30	95.40	97.63	98.65	97.28	97.82
	EBT	(55)	(66)	(101)	(109)	(183)	(182)	(244)	(226)	(87)	267
	EBT margin, %	(209.25)	(261.18)	(490.25)	(222.99)	(1,026.35)	(115.68)	(90.24)	(68.26)	(19.29)	30.56
	Net income	(55)	(66)	(101)	(109)	(183)	(184)	(247)	(227)	(89)	264
	Depreciation	2	2	2	1	1	1	0	(9)	(10)	(3)
Per share, $
Per share, $	Revenue	0.36	0.30	0.20	0.42	0.11	0.88	1.46	1.72	2.18	4.17
	Earnings	(0.75)	(0.78)	(0.98)	(0.94)	(1.09)	(1.03)	(1.33)	(1.18)	(0.43)	1.26
	Cash flow	(0.73)	(0.49)	(0.90)	(0.77)	(0.81)	(0.79)	(0.87)	(0.49)	(0.25)	1.66
	Capex	(0.07)	0.00	0.00	0.00	0.00	(0.01)	(0.01)	(0.01)	(0.01)	(0.01)
	Free cash flow	(0.80)	(0.49)	(0.90)	(0.78)	(0.81)	(0.81)	(0.88)	(0.51)	(0.26)	1.65
	Book value	0.02	0.99	0.48	0.33	(0.12)	(0.60)	(1.58)	(2.37)	(2.30)	(0.57)
	Shares, m	74	84	103	116	167	179	186	192	207	210
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.24
	P/S	17.79	18.24	40.32	8.17	69.96	15.78	7.86	3.52	3.45	1.87
	P/B	297.04	5.48	16.91	10.43	0.00	0.00	0.00	0.00	0.00	0.00
	EV/Sales	16.62	14.60	36.77	6.45	68.66	16.31	9.01	4.87	4.58	2.11
	EV/FCF	(7.46)	(8.87)	(8.17)	(3.50)	(9.02)	(17.73)	(14.95)	(16.58)	(38.84)	5.34
Cash, $m
Cash, $m	Operating cash flow	(53)	(41)	(93)	(90)	(135)	(142)	(162)	(95)	(52)	347
	Capex	(5)	0	0	0	(1)	(2)	(1)	(2)	(1)	(2)
	Free cash flow	(59)	(41)	(93)	(90)	(136)	(145)	(163)	(97)	(53)	345
Balance, $m
Balance, $m	Working capital	13	51	45	72	218	462	411	346	262	208
	Total debt	54	26	33	54	280	593	737	838	831	481
	Net debt	(2)	(92)	(73)	(84)	(23)	82	312	447	510	206
	Shareholders’ equity	2	84	49	38	(19)	(107)	(295)	(456)	(476)	(119)
Returns, %
Returns, %	ROA	(51.97)	(49.07)	(62.29)	(67.61)	(71.69)	(39.89)	(43.42)	(42.46)	(17.65)	52.53
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	(544.24)	0.00	(4.71)	245.61
	ROE	(223.70)	(154.16)	(152.26)	(248.94)	(1,925.37)	291.59	123.07	60.40	19.08	(88.68)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HCM HUTCHMED (China) Limited Sponsored ADR	$2.4B	— (loss-making)	—	+510.07% (above 0%: growing)	+419.25% (above 0%: growing)	+113.21% (above 0%: growing)	60.90%	0.00%	Compare
PBH Prestige Consumer Healthcare Inc.	$2.3B	13.9×	10.3×	+6.48% (above 0%: growing)	−36.46% (below 0%: shrinking)	−14.19% (below 0%: shrinking)	51.25%	19.77%	Compare
SUPN Supernus Pharmaceuticals, Inc.	$2.3B	— (loss-making)	103×	+32.40% (above 0%: growing)	n/m	−109.26% (below 0%: shrinking)	84.63%	(26.46%)	Compare
PRGO Perrigo Company plc	$2.3B	— (loss-making)	— (loss-making)	−3.17% (below 0%: shrinking)	n/m	+18.37% (above 0%: growing)	30.69%	2.31%	Compare
ALVO Alvotech	$2.1B	— (loss-making)	8.9×	+2,310.95% (above 0%: growing)	−99.51% (below 0%: shrinking)	−496.58% (below 0%: shrinking)	56.47%	9.14%	Compare
BCRX BioCryst Pharmaceuticals, Inc.	$2.1B	— (loss-making)	— (loss-making)	+33.61% (above 0%: growing)	+1,450.00% (above 0%: growing)	+153.22% (above 0%: growing)	98.24%	45.12%
XERS Xeris Biopharma Holdings, Inc.	$1.8B	— (loss-making)	54.5×	+28.74% (above 0%: growing)	n/m	+8,403.09% (above 0%: growing)	86.41%	5.62%	Compare
ANIP ANI Pharmaceuticals, Inc.	$1.7B	14.9×	14.5×	+25.87% (above 0%: growing)	+194.59% (above 0%: growing)	−22.19% (below 0%: shrinking)	62.35%	15.21%	Compare
PAHC Phibro Animal Health Corporation	$1.5B	15.8×	11.1×	+4.77% (above 0%: growing)	+28.57% (above 0%: growing)	−35.73% (below 0%: shrinking)	33.88%	12.14%	Compare
Median of peers	$2.2B	14.9×	12.8×	+27.31%	+28.57%	−18.19%	58.69%	7.38%

All 86 Drug Manufacturers Specialty & Generic stocks →

BioCryst Pharmaceuticals, Inc. (BCRX) key facts

Strength: BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
BioCryst Pharmaceuticals, Inc. (BCRX) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
Net income was $263.9 million, or $1.26 per share (basic), a net margin of 30.2%.
As of October 16, 2026, BCRX traded at $7.79, a market capitalization of $2.1 billion.
Return on equity was −88.7% and debt-to-equity -1.85.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 1.83 (grey zone) for fiscal 2025.